GlassScriptPhysician profile
Dhirendra N Das
NPI 1356440747
$8,233.04
in general payments reported to CMS, 2019-2025
29 companies · $651 in 2025
The $651 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,261 · 2020: $1,180 · 2021: $1,477 · 2022: $956 · 2023: $909 · 2024: $798 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,180 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,179.50 |
| Education | $178.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,497.68 | 2019-2025 | Jardiance |
| Amgen INC. | $826.50 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $600.39 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $579.17 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $557.51 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $467.91 | 2019-2024 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $452.28 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $325.48 | 2020-2023 | Brilinta |
| Boston Scientific Corporation | $302.06 | 2019-2022 | |
| Esperion Therapeutics, INC. | $295.23 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $272.40 | 2024 | Opsumit, Uptravi |
| Atricure, INC. | $210.22 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $184.61 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $160.43 | 2019-2020 | |
| Novo Nordisk INC | $118.03 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $68.60 | 2019 | |
| Paratek Pharmaceuticals, INC. | $46.06 | 2024-2025 | Nuzyra |
| Arbor Pharmaceuticals, INC. | $43.82 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.42 | 2021 | |
| Scpharmaceuticals INC. | $31.55 | 2023 | |
| Amarin Pharma, INC. | $25.56 | 2019-2021 | |
| Irhythm Technologies, INC. | $23.75 | 2020 | |
| Abbott Laboratories | $21.95 | 2024 | Mitraclip |
| Bridgebio Pharma, INC. | $16.96 | 2025 | Attruby |
| Kowa Pharmaceuticals America, INC. | $14.38 | 2019 | |
| Abbvie INC. | $13.98 | 2021 | |
| Siemens Medical Solutions USA, INC. | $13.89 | 2025 | |
| G Medical Diagnostic Services, INC. | $12.32 | 2022 | |
| Allergan, INC. | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhirendra Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.